NeoGenomics Q4 revenue up 11% to $190 million; full-year net loss widens to $108 million
NeoGenomics reported fourth-quarter and full-year 2025 results on February 17, 2026, with full-year revenue up 10% to $727 million and a full-year net loss of $108 million, up 37% from 2024. The company also issued 2026 guidance calling for revenue of $793 million to $801 million and a net loss of $50 million to $63 million, which matters to shareholders because it sets the company's first public outlook for 2026.
Key points
- Q4 2025 revenue rose 11% to $190 million; Q4 net loss narrowed 36% to $10 million
- Full-year 2025 net loss was $108 million, up from $79 million in 2024, including $27.8 million in impairment charges
- 2026 guidance: revenue of $793 million to $801 million, net loss of $50 million to $63 million, adjusted EBITDA of $55 million to $57 million
- The filing says the RaDaR ST patent litigation was successfully resolved
The filing
Written by AI on Nov 8, 2026, 6:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.